<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D8C3EF0-2A9D-4001-81E2-F0A7AAA54256"><gtr:id>4D8C3EF0-2A9D-4001-81E2-F0A7AAA54256</gtr:id><gtr:name>Imagen Biotech</gtr:name><gtr:address><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Dentistry</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D8C3EF0-2A9D-4001-81E2-F0A7AAA54256"><gtr:id>4D8C3EF0-2A9D-4001-81E2-F0A7AAA54256</gtr:id><gtr:name>Imagen Biotech</gtr:name><gtr:address><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FF3C4FB8-106D-4AC1-A06A-40C3D375EE86"><gtr:id>FF3C4FB8-106D-4AC1-A06A-40C3D375EE86</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE527239%2F1"><gtr:id>E32C7655-F9F3-49F7-85AD-7C76A0D64DD3</gtr:id><gtr:title>Bulk culture of commercially viable embryonic stem cells.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E527239/1</gtr:grantReference><gtr:abstractText>Dr Ward has developed and patented an enabling technology that permits the growth of embryonic stem cells in high density 3D cultures without the need for potentially harmful mouse feeder lines and expensive growth factors. The technology helps maintain ES cells in an undifferentiated state for prolonged periods (at least 30 days) and can significantly reduce the technical burden associated with current methods. By offering a route to simple, cost effective large volume culture of both mouse and human ES cells we will help to transform the utility of stem cells and widen their use as research tools and ultimately as therapeutic treatments of degenerative diseases. The objectives of this study are:- 1) Optimize and refine methods fro 3D stem cell culture; 2) Construct ES cell lines and media formulations for sale to the research community; 3) Produce a 'best practice' translatable manufacturing process; 4) To promote and market the technology to potential development partners and licensees.</gtr:abstractText><gtr:fund><gtr:end>2008-05-13</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-05-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>90274</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Reading</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy Reading</gtr:department><gtr:description>Prof Ben Whalley</gtr:description><gtr:id>9DFEEF41-9D97-489E-9265-142C45DF44B3</gtr:id><gtr:impact>Manuscript currently being written</gtr:impact><gtr:outcomeId>546076b5e93ed8.31834841-1</gtr:outcomeId><gtr:partnerContribution>Confidential</gtr:partnerContribution><gtr:piContribution>Confidential</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imagen Biotech</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Imagen-biotech</gtr:description><gtr:id>2C9029B7-D578-4E33-BDF0-A4E1C5825E16</gtr:id><gtr:impact>Technology still in development</gtr:impact><gtr:outcomeId>5457c06b493913.41131638-1</gtr:outcomeId><gtr:partnerContribution>Development of an Alzheimer's disease drug screening platform</gtr:partnerContribution><gtr:piContribution>Provision of iPS cells derived from Alzheimer's disease patients for use in drug screening applications.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biochemistry</gtr:department><gtr:description>Dr Richard Wade-Martins</gtr:description><gtr:id>79E4A89F-FCBF-4DE9-804E-953A33BB87CB</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:outcomeId>5460776895bba1.05850616-1</gtr:outcomeId><gtr:partnerContribution>Confidential</gtr:partnerContribution><gtr:piContribution>Confidential</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited research talk. Uppsala University, Sweden. 13th May 2015.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E789964D-1999-492F-8E5D-860586F98FBB</gtr:id><gtr:impact>Invited research talk. Uppsala University, Sweden. 13th May 2015.</gtr:impact><gtr:outcomeId>56dd9d9503a8a4.89989729</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chair/keynote speaker: 'The 2014 Regenerative Medicine Event: Stem Cell Reprogramming' meeting</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B967AD00-1C8C-4E6E-9C0D-67B9B92EDF95</gtr:id><gtr:impact>Talk sparked questions and discussion

Potential collaborators identified</gtr:impact><gtr:outcomeId>545c9317c84218.64745564</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Maths in Medicine Workshop. Keele University 10th-14th Sept 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BEC97A23-70A3-4C88-AD47-01059F77ADDA</gtr:id><gtr:impact>Mathematical modelling of microarray data achieved.

Further collaborations identified</gtr:impact><gtr:outcomeId>545cd6f3dedbe2.23070882</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TSB Stratified Medicine strategy on neurodegenerative diseases workshop. October 2013</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8211456B-E465-4947-A2AD-D2578D00075A</gtr:id><gtr:impact>Discussion/workshop on TSB Stratified Medicine strategy on neurodegenerative diseases

Recommendations made</gtr:impact><gtr:outcomeId>545cdaa189b514.79132047</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBSRC Next Generation Conference - commercialisation of research. November 2008.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6E9DEC49-2DA0-420F-9623-33C7CBA4D3C6</gtr:id><gtr:impact>Discussion of commercialisation of research

Potential commercial collaborators identified</gtr:impact><gtr:outcomeId>545cd8a87ac272.28751320</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited lecture: Keystone Symposia A8 2011 Epithelial Plasticity and Epithelial to Mesenchymal Transition, Jan 21 - Jan 26, 2011, Vancouver, British Columbia.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7473A1C2-4B5B-4F7B-AB1C-DCB5CCE72A0E</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards.

Academic and commercial collaborators identified</gtr:impact><gtr:outcomeId>545cd5ec4f8736.02985567</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EPSRC Stem cell strategy development panel. Royal Society, London. Panel member. 16th March 2009</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>55EB5924-0D25-4472-9B04-2F5344F1F613</gtr:id><gtr:impact>Discussion of EPSRC stem cell strategy

Final recommendations presented</gtr:impact><gtr:outcomeId>545cd96f16b1a5.97340174</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited lecture: Enabling Technologies for Stem Cell and Regenerative Medicine Research. Cambridge 28th November 2012.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>63243773-6C39-4AA0-920C-E00A9C6475F1</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Industry collaborators identified</gtr:impact><gtr:outcomeId>545cd572d4b727.03951913</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>High throughput screening strategies for neuromuscular disease. TREAT-NMD. Netherlands. 27th Feb - 1st March 2009.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>21C4AE12-4910-4CB9-80DB-3E46A402E96C</gtr:id><gtr:impact>Discussion of development of tools that industry, clinicians and scientists need to bring novel therapeutic approaches through preclinical development and into the clinic, and on establishing best-practice care for neuromuscular patients worldwide.

Report produced</gtr:impact><gtr:outcomeId>545cd7cd068e27.86315463</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Abcam Stem Cell Conference 2009, Antigua. 19th to 22nd of November 2009.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6172279F-0170-4980-B622-FCCC36C97717</gtr:id><gtr:impact>Talk sparked questions and discussion

New collaborations identified</gtr:impact><gtr:outcomeId>545cd6602675a2.69442470</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>925B68E9-D2EB-4EEA-9503-F01B3A19C87B</gtr:id><gtr:impact>MSCA Annual Scientific Meeting, 8th December 2015, Sheffield University, UK.</gtr:impact><gtr:outcomeId>56dd9c875e2712.30477106</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited lecture: Stem Cells in Drug Discovery conference, 2-3 June 2015, Cambridge University, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4799587A-E995-4762-A1A5-3C1CCD693811</gtr:id><gtr:impact>Stem Cells in Drug Discovery conference, 2-3 June 2015, Cambridge University, UK</gtr:impact><gtr:outcomeId>56dd9d2e02bc21.63148059</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The role of BBSRC, TSB and MRC in funding commercial initiatives. BBSRC HQ. Panel member. August 2008</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D884BD8E-D1C2-44BF-A6B4-C20ACD8F82D3</gtr:id><gtr:impact>Workshop discussing the roles of BBSRC, TSB and MRC in funding commercial initiatives.

Recommendations made</gtr:impact><gtr:outcomeId>545cdb1985dc17.58296361</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>62537</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IAA Concept study</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>E4BFD198-4AAF-4BFF-A47E-B02C4BE3C5EE</gtr:id><gtr:outcomeId>56dd9b8c572533.30986548</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6091000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPUK: Integrated Dementia Research Environment</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0AF4A267-DF36-4D17-A69D-239867261B60</gtr:id><gtr:outcomeId>56dd9ab8c64d23.42514071</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35243</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>EPSRC KTA Knowledge Transfer Account</gtr:department><gtr:description>Microfluidic Modulation of Embryonic Stem Cell Differentiation in Well-Defined Microscopic Flow (KTA Award 104: 2010-2011).</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>University of Sheffield</gtr:fundingOrg><gtr:id>02377704-BA3C-4B9D-92A5-7DDD220E9807</gtr:id><gtr:outcomeId>545cdece2ff521.05402337</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>216979</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC follow-on-fund</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K020277/1</gtr:fundingRef><gtr:id>31497F48-601F-45FC-B346-32AA23F4BEFE</gtr:id><gtr:outcomeId>545ce0326ad3f4.40528373</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2637207</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Stem cell call</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/H046070/1</gtr:fundingRef><gtr:id>7DAB2C74-DF61-4B16-9732-80FB7B2DA5A6</gtr:id><gtr:outcomeId>545ce10822eb42.71717200</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>57000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proximity to Discovery Secondment Grant</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1568E9A5-0EF3-45B3-BBCC-3B89EA01746B</gtr:id><gtr:outcomeId>56dd99feb3e5f6.39161068</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13319</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Pathfinder award</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>8E68DD9E-667A-4704-B2C0-0D368F0A1E4B</gtr:id><gtr:outcomeId>545cdf3f89dfe2.54799263</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2329271</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>UK UKDP: Integrated Dementia Research Environment</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M009076/1</gtr:fundingRef><gtr:id>302FF0DB-437E-4F04-86BD-8494F49860C1</gtr:id><gtr:outcomeId>545cdfc9970588.12507154</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neuratect: Human iPSC neuronal network platform for neurotoxicity screening</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>008E9975-038D-4187-9018-F95E86209445</gtr:id><gtr:outcomeId>56dd9b28e508e7.61962552</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>81956</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Crack-It UnTangle NC3Rs</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:fundingRef>35529-259127</gtr:fundingRef><gtr:id>E3327DC7-7B0E-46B6-AC8E-90161D9CD64B</gtr:id><gtr:outcomeId>545ce0ab63fc65.62698695</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>117000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Manchester, The</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>University of Manchester</gtr:fundingOrg><gtr:fundingRef>PoP fund</gtr:fundingRef><gtr:id>373DEF83-B0FF-4FB3-B4DB-DBD3E3D9B732</gtr:id><gtr:outcomeId>5ee2c75c5ee2c770</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>3 x patents filed from this technology and a spin-out company formed</gtr:description><gtr:firstYearOfImpact>2008</gtr:firstYearOfImpact><gtr:id>50473A47-0D4C-498F-A1F4-63C7D8CDBB1B</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54607cdd207660.14697378</gtr:outcomeId><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The work from this grant has enabled a patent application to be filed on the identification of biomarkers for the automated analysis of abnormal epithelium</gtr:description><gtr:grantRef>BB/E527239/1</gtr:grantRef><gtr:id>D5F05F90-4DCB-4BDC-8B01-6AF3ED3020D5</gtr:id><gtr:impact>Patent was filed February 2017</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58b6dea71e24d3.07957639</gtr:outcomeId><gtr:patentId>P33974GB1/RSM</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Patent application 2017</gtr:title><gtr:yearProtectionGranted>2017</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Method for the derivation of neural stem cells from human pluripotent stem cells.</gtr:description><gtr:grantRef>BB/E527239/1</gtr:grantRef><gtr:id>6C56A4C9-8974-4753-BDF8-A65C31B92BBA</gtr:id><gtr:impact>Non-exclusive research licence awarded to Imagen-Biotech Ltd</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>5457be9eae9f11.17753926</gtr:outcomeId><gtr:patentId>WO2014072720</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>A novel method for the derivation of neural stem cells from human pluripotent stem cells</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Protection of a method for the culture of ES and iPS cells in suspension</gtr:description><gtr:grantRef>BB/E527239/1</gtr:grantRef><gtr:id>B24C5109-54F3-49CB-AB57-4AB23DEA5BD7</gtr:id><gtr:impact>Further E-cadherin inhibiting peptides have been developed and patented.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>5457be3923e408.47659450</gtr:outcomeId><gtr:patentId>WO2007088372</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Method for the controlled isolation and culture of pluripotent stem cells</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Peptides developed for the culture of human and mouse ES cells in suspension culture</gtr:description><gtr:exploitationPathways>Spin-out company formed to exploit project outcomes</gtr:exploitationPathways><gtr:id>72DDFEDB-558E-4BC7-AD17-EAE855027C23</gtr:id><gtr:outcomeId>54607d2528a5d1.40680896</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EPSRC Stem cell strategy development panel. Royal Society, London. Panel member. 16th March 2009.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>13D07D9A-3A70-4F56-93A0-3C46098BC11A</gtr:id><gtr:impact>Stem cell call funded by EPSRC</gtr:impact><gtr:outcomeId>545cdc54c1b776.67381599</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>TSB Stratified Medicine strategy on neurodegenerative diseases workshop October 2013</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>951B5A36-0DF2-4453-8B7A-D572B7BF4AFA</gtr:id><gtr:impact>Call for neurodegenerative diseases funded</gtr:impact><gtr:outcomeId>545cdbe7331ea7.92890041</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Alzheimer's disease diagnostic</gtr:description><gtr:id>C9656D7D-2CFA-4842-9127-6374FA06DBF7</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>5457bf301b61f1.54436137</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Alzheimer's disease diagnostic</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Microarray analysis of E-cadherin inhibition in mouse and human ES cells and mammary epithelial tumour cells has been analysed</gtr:description><gtr:id>632D9F1A-879B-48A1-A2DE-F01DB27DB257</gtr:id><gtr:impact>Evidence that E-cadherin plays a major part in regulating signalling pathways, proliferation and apoptosis in ES and tumour cells</gtr:impact><gtr:outcomeId>5458ae3698aa31.36055627</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Microarray analysis of E-cadherin inhibition in cells</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Small peptides developed during this grant has been used to derive homogeneous populations of neural progenitor cells from iPSCs (human and mouse).</gtr:description><gtr:id>76179F31-07C5-41AC-846E-45C286D4D693</gtr:id><gtr:impact>NC3Rs Phase 1 grant award for the development of a Tau cell model</gtr:impact><gtr:outcomeId>5458ad89adaac6.05600916</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Differentiation of iPSCs to neural progenitor cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Small peptides developed during this grant that allows the culture of iPSCs and ES cells (human and mouse) in suspension culture.</gtr:description><gtr:id>F72C1A53-38BC-4DB0-AD84-00EA4E9C66C1</gtr:id><gtr:impact>Industry collaborations with Lonza.</gtr:impact><gtr:outcomeId>545ce26df22570.00093495</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Suspension culture of ES/iPS cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Small peptides have been developed during this grant that enable modification of gene transcript expression in embryonic stem cells</gtr:description><gtr:id>2677AE58-66E4-4DDF-9741-7806A72ED401</gtr:id><gtr:impact>Several papers published by me and collaborators published</gtr:impact><gtr:outcomeId>545ce1c8cb72a5.02465321</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Peptide development</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>StrataStem Ltd</gtr:companyName><gtr:description>Biotech Start-up</gtr:description><gtr:id>AB04C382-6A77-4EE9-A07D-958DADA6A512</gtr:id><gtr:impact>Biotech Start-up</gtr:impact><gtr:outcomeId>5457b9af8cb243.05332286</gtr:outcomeId><gtr:yearCompanyFormed>2012</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>6AEB7A94-33BA-4CCB-8E3E-1B279B519FE3</gtr:id><gtr:title>Using cadherin expression to assess spontaneous differentiation of embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/674ecea9cf4ffffb25a553cf05533601"><gtr:id>674ecea9cf4ffffb25a553cf05533601</gtr:id><gtr:otherNames>Spencer H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5457b54e2abf37.22436180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B7D0889-C104-4DA2-A471-ECC7D14500A7</gtr:id><gtr:title>E-cadherin and, in its absence, N-cadherin promotes Nanog expression in mouse embryonic stem cells via STAT3 phosphorylation.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c64929b77237ad6dcfa3dadf2b85a4e6"><gtr:id>c64929b77237ad6dcfa3dadf2b85a4e6</gtr:id><gtr:otherNames>Hawkins K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>5457b54f5bac46.85604260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>683D9383-224E-4010-B0E8-3C6E275DA538</gtr:id><gtr:title>Sox2 is essential for formation of trophectoderm in the preimplantation embryo.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ee4d9bcbab079c3db06775036a85b7"><gtr:id>d4ee4d9bcbab079c3db06775036a85b7</gtr:id><gtr:otherNames>Keramari M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5457b54e4fee12.87639329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>839D95F2-7285-461B-B88E-4E1F7341B2D9</gtr:id><gtr:title>Familial Alzheimer's disease modelling using induced pluripotent stem cell technology.</gtr:title><gtr:parentPublicationTitle>World journal of stem cells</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8b3542ab0bf3972e2cf67bb103b0577"><gtr:id>f8b3542ab0bf3972e2cf67bb103b0577</gtr:id><gtr:otherNames>Mohamet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1948-0210</gtr:issn><gtr:outcomeId>5457b54f7f92d5.65031237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8F411B5-A39A-4086-B56B-243BE19A0A14</gtr:id><gtr:title>High throughput cryopreservation of cells by rapid freezing of sub-?l drops using inkjet printing--cryoprinting.</gtr:title><gtr:parentPublicationTitle>Lab on a chip</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee1e37719dbf74d7391c6b36e5a96289"><gtr:id>ee1e37719dbf74d7391c6b36e5a96289</gtr:id><gtr:otherNames>Dou R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1473-0189</gtr:issn><gtr:outcomeId>5675e8d16e369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42BF3BDB-E001-4933-91DA-64EEF8037D8C</gtr:id><gtr:title>Novel peptides for deciphering structural and signalling functions of E-cadherin in mouse embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/257b181f27a114315e1f5314c7c8d6ee"><gtr:id>257b181f27a114315e1f5314c7c8d6ee</gtr:id><gtr:otherNames>Segal JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b6db4b150262.26535889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF2B96BC-3C3F-4823-AAF0-5CC3958C5E79</gtr:id><gtr:title>Novel cell lines isolated from mouse embryonic stem cells exhibiting de novo methylation of the E-cadherin promoter.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c64929b77237ad6dcfa3dadf2b85a4e6"><gtr:id>c64929b77237ad6dcfa3dadf2b85a4e6</gtr:id><gtr:otherNames>Hawkins K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>5457b54fa49b18.30078873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE4ABBC2-FED0-450F-8F95-CB5F24A4A307</gtr:id><gtr:title>Abrogation of E-cadherin-mediated cellular aggregation allows proliferation of pluripotent mouse embryonic stem cells in shake flask bioreactors.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8b3542ab0bf3972e2cf67bb103b0577"><gtr:id>f8b3542ab0bf3972e2cf67bb103b0577</gtr:id><gtr:otherNames>Mohamet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5457b54e02e862.58251065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66B7727C-705B-4DE0-BEE9-2F42218470AC</gtr:id><gtr:title>Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Journal of oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8b3542ab0bf3972e2cf67bb103b0577"><gtr:id>f8b3542ab0bf3972e2cf67bb103b0577</gtr:id><gtr:otherNames>Mohamet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1687-8450</gtr:issn><gtr:outcomeId>5457b54e77e8b9.35940609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51CB4C12-4A22-481B-A039-7D25595312BC</gtr:id><gtr:title>Abrogation of E-cadherin-mediated cell-cell contact in mouse embryonic stem cells results in reversible LIF-independent self-renewal.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20b5cfbc52ed06d7a222355b01c9d437"><gtr:id>20b5cfbc52ed06d7a222355b01c9d437</gtr:id><gtr:otherNames>Soncin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>5457b54daac2f5.42879236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>869AF522-C345-4620-B121-FD390E1D5BA9</gtr:id><gtr:title>E-cadherin acts as a regulator of transcripts associated with a wide range of cellular processes in mouse embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20b5cfbc52ed06d7a222355b01c9d437"><gtr:id>20b5cfbc52ed06d7a222355b01c9d437</gtr:id><gtr:otherNames>Soncin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5457b54ec9e4a5.92906767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA7DF024-E25B-4295-9838-0926D89E2AFE</gtr:id><gtr:title>The function of e-cadherin in stem cell pluripotency and self-renewal.</gtr:title><gtr:parentPublicationTitle>Genes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20b5cfbc52ed06d7a222355b01c9d437"><gtr:id>20b5cfbc52ed06d7a222355b01c9d437</gtr:id><gtr:otherNames>Soncin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2073-4425</gtr:issn><gtr:outcomeId>5457b5bd6904f6.56509101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D62EC01-2D2D-4D60-8BDB-013EE49BAE1B</gtr:id><gtr:title>Epithelial-mesenchymal transition events during human embryonic stem cell differentiation.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d18c2dcdd80cdac05fa0b34d4f8b3c3"><gtr:id>9d18c2dcdd80cdac05fa0b34d4f8b3c3</gtr:id><gtr:otherNames>Eastham AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5457b5bd37d4d1.12689062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCB58EE0-5B36-4B07-ADCF-6C54972A2467</gtr:id><gtr:title>E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87bbe8d49a73306244ba5547bef3a7a3"><gtr:id>87bbe8d49a73306244ba5547bef3a7a3</gtr:id><gtr:otherNames>Spencer HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn><gtr:outcomeId>5457b5bcdff492.87222935</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E527239/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>